The caspase-1 inhibitor VX-765 emerges as a promising therapeutic candidate for mitigating the progression of diabetic nephropathy, as it effectively suppresses caspase-1-mediated pyroptosis, renal inflammation, and fibrosis in diabetic mice [48]. This evidence concerns the gene CASP1 and diabetic kidney disease.